Geneva, Oct. 8 -- International Clinical Trials Registry received information related to the study (NCT07193550) titled 'A Phase 2 Trial of Zanzalintinib in Advanced/Metastatic Bone Sarcomas (ZAMBONE)' on Sept. 24.
Study Type: Interventional
Study Design:
Allocation: N/A. Intervention model: Single Group Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: M.D. Anderson Cancer Center
Condition:
Bone Sarcomas
Intervention:
Drug: Zanzalintinib
Recruitment Status: Not recruiting
Phase: Phase 2
Date of First Enrollment: May 31, 2026
Target Sample Size: 70
Countries of Recruitment:
United States
To know more, visit https://clinicaltrials.gov/study/NCT07193550
Published by HT Digital Content Se...